Lexaria Bioscience Corp. insider trading

Every open-market purchase and sale by Lexaria Bioscience Corp.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Lexaria Bioscience Corp.’s insiders pay?

From January 4, 2010 to July 30, 2025, 9 insiders reported 45 open-market purchases and 2 sales not made under a pre-set plan in Lexaria Bioscience Corp.

Lexaria Bioscience Corp.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Bunka Christopher	CEO	34	—	—	0	—	July 30, 2025
Docherty John Martin	President	4	—	—	0	—	June 24, 2016
Christopher Richard	Chief Executive Officer	2	—	—	0	—	July 30, 2025
Mckechnie William Edward	Director	1	—	—	1	—	May 31, 2018
Baxter Nicholas W	Director	1	—	—	0	—	December 31, 2014
Bhullar Baljinder	CFO	1	—	—	0	—	March 25, 2014
Carle Vanessa	Secretary	0	—	—	1	—	August 1, 2024
Demartini David	Director	1	—	—	0	—	January 4, 2010
Ihrke Thomas James	Sr. VP, Business Development	1	—	—	0	—	December 22, 2010

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Lexaria Bioscience Corp. · Funds · Politicians